Birgit Schultes

Birgit Schultes is the Chief Scientific Officer and Senior Vice President, Head of Cell Therapies at Intellia Therapeutics, Inc., leading efforts in genome editing to develop curative treatments for severe diseases using the CRISPR/Cas9 system since September 2017. Prior experience includes roles as Senior Director at Unum Therapeutics, focusing on cancer immunotherapy, and as Senior Director at Momenta Pharmaceuticals, overseeing pharmacology and translational research in oncology and autoimmune diseases. Birgit co-founded Advanced Immune Therapeutics to innovate cancer therapeutics and held senior research positions at United Therapeutics and AltaRex Corp., contributing to immune modulation and antibody development. Academic qualifications include a Ph.D. in Immunology from The University of Bonn, alongside advanced management development from Boston University.